Hyaluronic acid-green tea catechin micellar nanocomplexes: Fail-safe cisplatin nanomedicine for the treatment of ovarian cancer without off-target toxicity
Source abstract
Abstract
The green tea catechin, (-)-epigallocatechin-3-O-gallate (EGCG), has gained significant attention as a potent adjuvant to enhance the antitumor efficacy of cisplatin while mitigating its harmful side effects. Herein we report the development of a fail-safe cisplatin nanomedicine constructed with hyaluronic acid-EGCG conjugate for ovarian cancer therapy. A simple mixing of this conjugate and cisplatin induces spontaneous self-assembly of micellar nanocomplexes having a spherical core-shell structure. The surface-exposed hyaluronic acid enables efficient delivery of cisplatin into CD44-overexpressing cancer cells via receptor-mediated endocytosis whereas the internally packed EGCG moieties offer an environment favorable for the encapsulation of cisplatin. In addition, the antioxidant effect of EGCG moieties ensures fail-safe protection against off-target organ toxicity originating from cisplatin-evoked oxidative stress. Pharmacokinetic and biodistribution studies reveal the prolonged blood circulation and preferential tumor accumulation of intravenously administered nanocomplexes. Moreover, the nanocomplexes exhibit superior antitumor efficacy over free cisplatin while displaying no toxicity in both a subcutaneous xenograft model and peritoneal metastatic model of human ovarian cancer. Our findings demonstrate proof of concept for the feasibility of green tea catechin-based micellar nanocomplexes as a safe and effective cisplatin nanomedicine for ovarian cancer treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Inflammatory Biomarkers in Disease Prognosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. Global cancer statistics, 2012
2. Rethinking ovarian cancer: recommendations for improving outcomes10.1038/nrc3144 ↗
3. Nanoparticle formulations of cisplatin for cancer therapy10.1002/wnan.1390 ↗
4. Reversible cell-specific drug delivery with aptamer-functionalized liposomes10.1002/anie.200901452 ↗
5. Nanoparticles with precise ratiometric Co-Loading and Co-Delivery of gemcitabine monophosphate and cisplatin for treatment of bladder cancer10.1002/adfm.201401076 ↗
6. Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity10.1073/pnas.1203129109 ↗
7. The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo10.1016/j.addr.2012.10.002 ↗
8. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice
9. Core-shell polymer nanoparticles for prevention of GSH drug detoxification and cisplatin delivery to breast cancer cells10.1039/C5NR04963F ↗
10. Human serum albumin conjugated nanoparticles for pH and redox-responsive delivery of a prodrug of cisplatin10.1002/chem.201502756 ↗
11. Polymer cisplatin conjugate nanoparticles for acid-responsive drug delivery10.1021/nn9014032 ↗
12. Analysis of nanoparticle delivery to tumours10.1038/natrevmats.2016.14 ↗
13. Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate10.1158/0008-5472.CAN-05-3636 ↗
14. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance10.1038/nrc2641 ↗
15. Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating g2/m arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane10.1155/2013/872957 ↗
16. EGCG enhances cisplatin sensitivity by regulating expression of the copper and cisplatin influx transporter CTR1 in ovary cancer
17. Novel chemotherapeutic and renal protective effects for the green tea (EGCG): role of oxidative stress and inflammatory-cytokine signaling10.1016/j.phymed.2010.08.004 ↗
18. Epigallocatechin-3-gallate activates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats10.1016/j.lfs.2010.06.014 ↗
19. Mitochondrial modulation by Epigallocatechin 3-Gallate ameliorates cisplatin induced renal injury through decreasing oxidative/nitrative stress, inflammation and NF-kB in mice
20. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives10.1016/j.jconrel.2009.09.010 ↗
21. Self-assembled hyaluronic acid nanoparticles for active tumor targeting10.1016/j.biomaterials.2009.09.030 ↗
22. Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors10.1016/j.biomaterials.2013.01.077 ↗
23. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer10.18632/oncotarget.3220 ↗
24. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug10.1158/1078-0432.CCR-13-1536 ↗
25. Structural properties of green tea catechins10.1021/acs.jpcb.5b08737 ↗
26. Self-assembled micellar nanocomplexes comprising green tea catechin derivatives and protein drugs for cancer therapy10.1038/nnano.2014.208 ↗
27. Smart nanocarrier based on PEGylated hyaluronic acid for cancer therapy10.1021/nn202070n ↗
28. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy10.1146/annurev.pharmtox.48.080907.180426 ↗
29. Synthesis, characterization, and in vivo diagnostic applications of hyaluronic acid immobilized gold nanoprobes10.1016/j.biomaterials.2008.08.038 ↗
30. Drug release from nanomedicines: selection of appropriate encapsulation and release methodology10.1007/s13346-012-0064-4 ↗
31. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases10.1021/mp900242f ↗
32. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo10.1016/j.biomaterials.2016.01.049 ↗
33. Platinum drug distribution in cancer cells and tumors10.1021/cr9001066 ↗
34. Opposing influence of intracellular and membrane thiols on the toxicity of reducible polycations10.1016/j.biomaterials.2013.07.095 ↗
35. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats10.1016/0006-2952(87)90490-4 ↗
36. Cisplatin nephrotoxicity: molecular mechanisms
37. Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-kappaB activation and antioxidant defence10.1371/journal.pone.0105070 ↗
38. Ovarian cancer development and metastasis10.2353/ajpath.2010.100105 ↗
39. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence10.1038/nrclinonc.2009.217 ↗